Join

Compare · CHWY vs LOGC

CHWY vs LOGC

Side-by-side comparison of Chewy Inc. (CHWY) and ContextLogic Inc. (LOGC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CHWY and LOGC operate in Catalog/Specialty Distribution (Consumer Discretionary), so they compete in similar markets.
  • CHWY is the larger of the two at $8.44B, about 173.1x LOGC ($48.8M).
  • Over the past year, CHWY is down 56.7% and LOGC is up 0.0% - LOGC leads by 56.7 points.
  • LOGC has been more active in the news (9 items in the past 4 weeks vs 7 for CHWY).
  • CHWY has more recent analyst coverage (25 ratings vs 5 for LOGC).
PerformanceCHWY-51.68%LOGC+0.00%
2025-06-13+0.00%2026-06-08
MetricCHWYLOGC
Company
Chewy Inc.
ContextLogic Inc.
Price
$20.13-2.42%
$7.05+1.00%
Market cap
$8.44B
$48.8M
1M return
-14.92%
+0.00%
1Y return
-56.71%
+0.00%
Industry
Catalog/Specialty Distribution
Catalog/Specialty Distribution
Exchange
NYSE
NASDAQ
IPO
2019
2020
News (4w)
7
9
Recent ratings
25
5
CHWY

Chewy Inc.

Chewy, Inc., together with its subsidiaries, engages in the pure play e-commerce business in the United States. The company provides pet food and treats, pet supplies and pet medications, and other pet-health products, as well as pet services for dogs, cats, fish, birds, small pets, horses, and reptiles through its chewy.com retail Website, as well as its mobile applications. It offers approximately 70,000 products from 2,500 partner brands. The company was founded in 2010 and is headquartered in Dania Beach, Florida. Chewy, Inc. is a subsidiary of PetSmart, Inc.

LOGC

ContextLogic Inc.

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Latest CHWY

Latest LOGC